CMPX (Compass Therapeutics) Future 3-5Y EPS without NRI Growth Rate: N/A (As of Sep. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CMPX Compass Therapeutics Inc CMPX
26 GF Score
Price $2.31
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Compass Therapeutics's Future 3-5Y EPS without NRI Growth Rate is N/A.

Compass Therapeutics  (NAS:CMPX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Compass Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

CMPX vs ARCT, AVIR, BNTC: Future 3-5Y EPS without NRI Growth Rate Comparison

For the Biotechnology subindustry, Compass Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compass Therapeutics Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compass Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Compass Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.


CMPX
26GF Score
Compass Therapeutics Inc CMPX
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
26GF Score

Get the complete analysis for CMPX

Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.31
Price